{
  "docId": "019de515-1bf5-75fc-a19f-ef7a3323e229",
  "docSlug": "a43786f91ea3b101a0e62521077ddab4",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 14,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/10",
  "deckHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229",
  "deckJsonHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json",
  "deckAnchorHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.344,
        "x": 0.62,
        "y": 0.62
      },
      "kind": "image",
      "text": "World Health Organization WHO/BS/2023.2442 ENGLISH ONLY WHO Guideline on the nonclinical and clinical evaluation of monoclonal antibodies and related biological products intended for the prevention or treatment of human infectious diseases.",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12517f3f-66d9-405d-b85b-537a3a819f4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.369,
        "x": 0.595,
        "y": 0.298
      },
      "kind": "image",
      "text": "Joint EMA-FDA workshop: Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4eb2a54c-68f1-48fc-ad9e-e0c2d9c0bd59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.17,
        "w": 0.344,
        "x": 0.62,
        "y": 0.398
      },
      "kind": "image",
      "text": "ADVISORY COMMITTEE MEETING Vaccines and Related Biological Products Advisory Committee January 26, 2023 Meeting Announcement JANUARY 26, 2023",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "713022bd-498a-4113-91d7-695a79212679",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.53,
        "x": 0.045,
        "y": 0.27
      },
      "kind": "list",
      "text": "Regulators are seeking strategies to streamline development of monoclonal antibodies and vaccines\nThe necessity of streamlined development for new mAb products is supported by the science\nUnderstanding of SARS-CoV-2 biology has grown exponentially\nAccumulating data enables scientists to predict mAb effectiveness based on in vitro data which can then be confirmed in patients\nThis is especially true for products closely related to those previously studied",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44d388f9-c20b-404e-9ae7-41fbc97b9683",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.027,
        "w": 0.53,
        "x": 0.045,
        "y": 0.72
      },
      "kind": "title",
      "text": "Possible Implication: Advance medicines to patients faster",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57ef6d1c-e36e-4e7e-af0a-b004297309a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.706,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "REGULATORS CONSIDERING STRATEGIES TO ACCELERATE MONOCLONAL ANTIBODY DEVELOPMENT TIMELINES",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4092407e-ec84-4852-99db-1e3d4ccffc35",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0",
      "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.",
      "position": 1,
      "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}